Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

DRNA

Dicerna Pharmaceuticals (DRNA)

Dicerna Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:DRNA
FechaHoraFuenteTítuloSímboloCompañía
14/02/202205:18Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:DRNADicerna Pharmaceuticals Inc
10/01/202216:00Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)NASDAQ:DRNADicerna Pharmaceuticals Inc
03/01/202205:03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:DRNADicerna Pharmaceuticals Inc
29/12/202115:23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202110:18Edgar (US Regulatory)Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202110:15Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202110:06Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202109:52Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202109:47Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202108:35Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202108:29Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202108:04Business WireNovo Nordisk Announces Completion of Dicerna Pharmaceuticals AcquisitionNASDAQ:DRNADicerna Pharmaceuticals Inc
25/12/202107:00Business WireDicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire DicernaNASDAQ:DRNADicerna Pharmaceuticals Inc
09/12/202107:41PR Newswire (US)Direxion Launches mRNA ETF (MSGR)NASDAQ:DRNADicerna Pharmaceuticals Inc
08/12/202117:55TipRanksDicerna Pharma (DRNA) Gets a Hold Rating from Chardan CapitalNASDAQ:DRNADicerna Pharmaceuticals Inc
25/11/202103:09TipRanksLeerink Partners Keeps a Buy Rating on Dicerna Pharma (DRNA)NASDAQ:DRNADicerna Pharmaceuticals Inc
24/11/202116:07Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:DRNADicerna Pharmaceuticals Inc
24/11/202115:58Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:DRNADicerna Pharmaceuticals Inc
19/11/202106:16TipRanksDicerna Soars 78.7% on Novo Nordisk’s $3.3B Acquisition OfferNASDAQ:DRNADicerna Pharmaceuticals Inc
18/11/202116:32Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:DRNADicerna Pharmaceuticals Inc
18/11/202116:08Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:DRNADicerna Pharmaceuticals Inc
18/11/202110:47Dow Jones NewsDicerna Shares Soar on Takeover by Novo NordiskNASDAQ:DRNADicerna Pharmaceuticals Inc
18/11/202106:51Dow Jones NewsNovo Nordisk to Buy Dicerna for $38.25 a ShareNASDAQ:DRNADicerna Pharmaceuticals Inc
18/11/202106:00Business WireNovo Nordisk to Acquire DicernaNASDAQ:DRNADicerna Pharmaceuticals Inc
12/11/202107:54Dow Jones NewsDicerna Pharma: Two Targets in Lilly Collaboration Meet Proof of PrincipleNASDAQ:DRNADicerna Pharmaceuticals Inc
12/11/202107:10Business WireDicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With LillyNASDAQ:DRNADicerna Pharmaceuticals Inc
12/11/202107:00Business WireDicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021NASDAQ:DRNADicerna Pharmaceuticals Inc
09/11/202106:50Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:DRNADicerna Pharmaceuticals Inc
09/11/202106:30Business WireDicerna Announces Third Quarter 2021 Financial Results and Provides a Business UpdateNASDAQ:DRNADicerna Pharmaceuticals Inc
04/11/202112:15Business Wire Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021NASDAQ:DRNADicerna Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:DRNA